Dedicated budgets for medical publication teams 'linked to higher output'
Setting aside a dedicated budget for medical publication tends to be associated with a higher output of manuscripts and abstracts, a report has shown.
In-house medical publication teams that have dedicated budgets in place tend to produce a greater number of manuscripts and abstracts each year, a study has found.
Cutting Edge Information surveyed a number of pharmaceutical medical publications teams and found that more than nine in ten high-output teams had dedicated budgets.
The pharmaceutical intelligence firm observed that companies that commit to the production of medical publications in this way tend to have a higher output of material.
In contrast, just 67 per cent of low-output teams had dedicated budgets in place.
Ryan McGuire, research team leader at Cutting Edge Information, said: "High-output teams exist because their companies have committed to the medical publication group's objectives.
"The foremost and most basic statement of that commitment is to establish a dedicated budget."
Pharmaceutical companies that produce large numbers of medical publications tend to benefit from the greater exposure to doctors and other medical professionals, who may be more likely to prescribe their products.
Related News
-
News Novartis signs US$3.2 bn subcutaneous delivery deal with Alteogen
Swiss pharma giant secures access to Korean biotech's ALT-B4 hyaluronidase platform in milestone-heavy agreement, marking Alteogen's fourth major licensing deal of 2026 as competition intensifies in the subcutaneous drug delivery space.
-
News Women in Pharma: The philosophy of pharmaceutical leadership
In this latest instalment of our Women in Pharma series, we sit down with Clarissa Sowemimo-Coker, Chief Strategy Officer at Ambrose Healthcare and CPHI Middle East Advisory Board Member.
-
News The PSCI Supplier Partnership - Collaboration for Responsible Supply Chains
About the Pharmaceutical Supply Chain Initiative The Pharmaceutical Supply Chain Initiative (PSCI) is the leading, member-led association for pharmaceutical companies working collaboratively to build responsible supply chains. Founded in 2006 and es... -
News AstraZeneca shares plunge 8.9% after reports of BMS talks
Britain's largest drugmaker lost more than GBP£17 billion in market value following reports of preliminary merger discussions with Bristol Myers Squibb that could create a pharmaceutical giant worth nearly US$400 billion, though investors rem... -
News GSK announces £400 million investment in new Cambridge R&D centre
Pharmaceutical giant to establish flagship research facility on Cambridge Biomedical Campus as part of strategic pipeline acceleration
-
News The CPHI Sustainability Summit - Where Conversation Becomes Collaboration
The Report Was Never the Destination - “The future of pharmaceutical sustainability won’t be shaped by individual organisations working in isolation. It will be shaped by partnerships, shared expertise and the willingness to work diffe... -
News Trump's generic drug tariffs set to reshape global pharmaceutical supply chains
The US president has announced plans to impose tariffs of up to 200% on imported generic medicines from August 2028, giving manufacturers a two-year window to establish domestic production facilities. The move threatens to upend a global supply chain t... -
News Building Safer, More Responsible Pharmaceutical Supply Chains: PSCI Global Audit Insights
The Pharmaceutical Supply Chain Initiative (PSCI) has released its seventh annual Audit Findings Analysis Report, offering unprecedented insights into supplier practices across the global pharmaceutical and healthcare industry.With a record-breaking 24...